| Private Placement / Financing Transactions
AI Optics: The company raised $14.7 million of venture funding from undisclosed investors on August 22, 2025. The company is a manufacturer of a medical device designed to prevent blindness and vision loss.
EdgeX: The company raised $8.5 million of venture funding from undisclosed investors on August 21, 2025. The company is a developer of a wire-free enterprise edge intelligence software designed to allow hospitals to track mobile equipment by capturing intelligence about the location and status of people and assets.
Method AI: The company raised $20 million of Series A venture funding from Cleveland Clinic, JobsOhio Growth Capital and other undisclosed investors on August 21, 2025. The company is a developer of an AI surgical navigation platform designed to improve patient outcomes for robotic surgical oncology procedures.
Syncromune: The company raised $131.8 million in Series A venture funding from Wasatch Equity Partners and other undisclosed investors on August 21, 2025, putting the company’s pre-money valuation at $122.s million. The company is a developer of intratumoral immunotherapy designed to treat metastatic solid tumor cancers.
Thrive Health Tech: The company raised $5 million of venture funding from undisclosed investors on August 21, 2025. The company is a developer of a communication platform designed to improve mobile healthcare access and outcomes for underserved communities.
Trially: The company raised $4.7 million of venture funding from undisclosed investors on August 21, 2025. The company is a developer of an AI-powered clinical trial recruitment platform designed to streamline clinical research and catalyze advanced therapies.
Wellth: The company raised $36 million of Series C venture funding in a deal led by Mercato Partners on August 21, 2025. New York Life Ventures, Comcast Ventures, CD-Venture, SignalFire and FCA Venture Partners also participated in the round. The company is a developer of a digital healthcare platform designed to improve treatment adherence through behavioral economics.
Iantrek: The company raised $42 million of Series C venture funding in a deal led by U.S. Venture Partners on August 20, 2025, putting the company’s pre-money valuation at $53 million. JSD Capital, Civilization Ventures, Visionary Venture Fund, Sectoral Asset Management, aMoon Fund, and other undisclosed investors also participated in the round. The company is a developer of a minimally invasive technology designed for ophthalmic medical devices.
Molecular You: The company raised $5 million of Series A venture funding in a deal led by Voloridge Health on August 20, 2025. Dynamic Leap and other undisclosed investors also participated in the round. The company is a developer of a comprehensive health assessment platform designed to analyze and interpret an individual’s biological data.
Somite: The company raised an estimated $60 million of Series A venture funding in a deal led by Khosla Ventures on August 20, 2025, putting the company’s pre-money valuation at $105 million. Ajinomoto, Samsung NEXT Ventures, AMD Ventures, Fusion Fund, TechAviv Founder Partners, Harpoon Ventures, Pitango Venture Capital, SciFi VC, Fidji Simo, Martin Chavez, Chan Zuckerberg Initiative and other undisclosed investors also participated in the round. The company is a developer of a biotechnology platform designed to transform medical treatments, diseases, and therapeutic research approaches.
DeepSight Technology: The company closed on $60 million of an undisclosed targeted amount of Series C venture funding on August 19, 2025. The company is an operator of medical imaging technology intended to transform ultrasound into a precision platform for real-time guidance during interventional procedures.
Eight Sleep: The company raised $100 million of Series D venture funding in a deal led by Hongshan Capital Group on August 19, 2025. Valor Equity Partners, Founders Fund, Y Combinator, Zak Brown, Charles Leclerc and Atreides Management also participated in the round. The company is an operator of a sleep mattress product brand intended to improve and support optimal rest, health, and daily function.
Moonrise Medical: The company raised an undisclosed amount of venture funding from Providence Health Care Ventures and Government of Ontario on August 19, 2025. The company is a developer of an artificial intelligence-enabled ultrasound technology to help diagnose and manage peripheral vascular disease.
Neurovalens: The company raised GBP 6 million of venture funding through a combination of debt and equity on August 19, 2025. GBP 5 million of venture funding was led by Clarendon Fund Managers with participation from Whiterock, IQ Capital Partners, ACF Investors, Innovation Ulster and other undisclosed investors. A GBP 1 million loan was provided by Whiterock. The company is a developer of non-invasive neurostimulation products.
PowerPhotonic: The company raised GBP 2.6 million of venture funding from Archangel Investors and Maven Capital Partners on August 19, 2025, putting the company’s pre-money valuation at GBP 4.8 million. The company is a manufacturer of micro-optical fabrication technology equipment intended to offer a wide range of laser micro-optics products.
Aria CV: The company raised $3.6 million of Series C venture funding from KOFA Healthcare and other undisclosed investors on August 18, 2025, putting the company’s pre-money valuation at $65 million. The company is a developer of an implantable cardiovascular device designed to treat pulmonary hypertension.
Luna Diabetes: The company raised $23.6 million of Series A venture funding in a deal led by Vensana Capital on August 18, 2025, putting the company’s pre-money valuation at $21.9 million. Ascensia Diabetes Care, 2468 Ventures, Interlock Capital, Serpentine Ventures, Winklevoss Capital Management, and other undisclosed investors also participated in the round. The company is a manufacturer of an automated insulin delivery system designed for overnight use by insulin pen users.
Pattern: The company raised $44.2 million of Series D venture funding from undisclosed investors on August 18, 2025, putting the company’s pre-money valuation at an estimated $60.8 million. The company is a provider of a single-cell microbiology antimicrobial treatment intended to simplify antibiotic selection for life-threatening infections.
|
